Although the direct blockade of IL-17 with either fully human or humanized monoclonal antibodies, such as secukinumab and ixekizumab, respectively, may be the most straightforward approach for RA, results from clinical trials revealed lower clinical efficacy than expected for these compounds. This evidence concerns the gene IL17A and rheumatoid arthritis.